石药集团(01093.HK) 公布,集团自主研发的化学1类新药SYH2068注射液(双链小干扰RNA)获中国国家药品监督管理局批准,可以在内地开展临床试验。该产品适用于治疗高脂蛋白血症,通过优化序列和化学修饰的策略来实现更持久的基因沉默效果,具有预防动脉粥样硬化性心血管疾病的潜力。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-25 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.